Insider Buying: Repligen Co. (NASDAQ:RGEN) CEO Acquires $248,160.00 in Stock

Repligen Co. (NASDAQ:RGENGet Free Report) CEO Anthony Hunt purchased 2,000 shares of Repligen stock in a transaction that occurred on Friday, June 14th. The stock was purchased at an average price of $124.08 per share, with a total value of $248,160.00. Following the transaction, the chief executive officer now owns 165,177 shares in the company, valued at approximately $20,495,162.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Anthony Hunt also recently made the following trade(s):

  • On Tuesday, May 21st, Anthony Hunt sold 20,072 shares of Repligen stock. The shares were sold at an average price of $168.26, for a total transaction of $3,377,314.72.

Repligen Trading Down 0.3 %

Shares of NASDAQ RGEN opened at $125.62 on Monday. The business has a 50 day simple moving average of $160.57 and a 200 day simple moving average of $176.55. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13. The stock has a market cap of $7.02 billion, a price-to-earnings ratio of 502.50, a PEG ratio of 4.19 and a beta of 1.04. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35.

Repligen (NASDAQ:RGENGet Free Report) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.01). The business had revenue of $151.31 million during the quarter, compared to the consensus estimate of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. The business’s revenue was down 17.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.64 earnings per share. On average, research analysts predict that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Repligen

Institutional investors have recently bought and sold shares of the stock. YHB Investment Advisors Inc. bought a new stake in shares of Repligen during the 1st quarter worth about $26,000. Lazard Asset Management LLC lifted its holdings in Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in Repligen by 152.1% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 146 shares during the period. Principal Securities Inc. acquired a new position in Repligen during the fourth quarter valued at approximately $48,000. Finally, CWM LLC raised its position in shares of Repligen by 19.9% in the first quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 60 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on RGEN shares. JPMorgan Chase & Co. dropped their price target on Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. Stifel Nicolaus upped their target price on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from, Repligen currently has an average rating of “Moderate Buy” and an average price target of $197.75.

View Our Latest Analysis on RGEN

Repligen Company Profile

(Get Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Stories

Insider Buying and Selling by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with's FREE daily email newsletter.